跳转至内容
Merck
CN

SML2955

Mirodenafil dihydrochloride

≥98% (HPLC)

别名:

4-[[3-(5-Ethyl-4,5-dihydro-4-oxo-7-propyl-1H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl]sulfonyl]-1-piperazineethanol, dihydrochloride, 5-Ethyl-2-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl]-2-propoxyphenyl]-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one, dihydrochloride, 5-Ethyl-3,5-dihydro-2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one, dihydrochloride, SK 3530 dihydrochloride, SK-3530 dihydrochloride, SK3530 dihydrochloride

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C26H37N5O5S·2HCl
化学文摘社编号:
862189-96-6
分子量:
604.59
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD28139019

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

[S](=O)(=O)(N4CCN(CC4)CCO)c1cc(c(cc1)OCCC)c2[nH][c](c3[n](cc(c3n2)CCC)CC)=O.Cl.Cl

InChI

1S/C26H37N5O5S.2ClH/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32;;/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33);2*1H

InChI key

CKPHITUXXABKDL-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

相关类别

Biochem/physiol Actions

Mirodenafil (SK3530) is an orally active, highly potent and selective phosphodiesterase-5 (PDE5) inhibitor (IC50 = 338 pM). with therapeutic efficacy in various ED models in vivo. Comparing to sildenafil, mirodenafil shows ~10-times higher PDE5 selectivity in vitro and remains longer in the plasma and corpus cavernosum following oral dosing at 40 mg/kg in rats in vivo.
Orally active, highly potent and selective phosphodiesterase-5 (PDE5) inhibitor with ED therapeutic efficacy in vivo.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000119244
0000119448
0000106108

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Hoon Choi et al.
International neurourology journal, 19(1), 19-26 (2015-04-04)
To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group); untreated, CBI model rats (CBI group); and CBI
Young H Choi et al.
Biopharmaceutics & drug disposition, 30(6), 305-317 (2009-07-30)
The pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous (5, 10, 20 and 50 mg/kg) and oral (10, 20 and 50 mg/kg) administration of mirodenafil, and the first-pass effect of mirodenafil after intravenous, oral, intraportal, intragastric
Ji-Youn Jung et al.
The Journal of veterinary medical science, 70(11), 1199-1204 (2008-12-06)
Mirodenafil (SK3530) is a new potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5). Recent clinical trials have demonstrated that mirodenafil is an effective treatment for erectile dysfunction. Its mechanism of action is enhancement of nitric oxide (NO) induced
Ji Sung Shim et al.
Urology, 91, 244-244 (2016-02-28)
To evaluate the distribution of a daily phosphodiesterase type 5 inhibitor dose (mirodenafil) in rat plasma and bladder and prostate tissue in a model of atherosclerosis-induced chronic pelvic ischemia. Thirty-two 18-week-old male Sprague Dawley rats were divided into two groups.
Jae Heon Kim et al.
The world journal of men's health, 38(3), 345-352 (2019-08-07)
To validate a novel arteriogenic erectile dysfunction (ED) model with atherosclerosis (AS) based on molecular and histologic evidence induced by chronic pelvic ischemia (CPI) and determine effect of phosphodiesterase-5 inhibitor treatment. Twenty 16-week-old male Sprague-Dawley rats were divided into three
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持